Literature DB >> 9108764

Change in the use of breast-conserving surgery in western Washington after the 1990 NIH Consensus Development Conference.

D Lazovich1, E White, D B Thomas, R E Moe, S Taplin.   

Abstract

OBJECTIVE: To evaluate the use of breast-conserving surgery in western Washington before and after the National Institutes of Health Consensus Development Conference (June 18-21, 1990) during which breast-conserving surgery was recommended for most women with early invasive breast cancer.
DESIGN: Survey.
SETTING: Population-based cancer registry in the Seattle-Puget Sound (Washington) region. PARTICIPANTS: The survey included 13541 women in whom American Joint Committee on Cancer stage I or II breast cancer was diagnosed between January 1, 1983, and December 31, 1993. MAIN OUTCOME MEASURE: Proportion of participants who underwent breast-conserving surgery.
RESULTS: From April 1985, after results of a US randomized controlled trial showing equivalent survival in women undergoing mastectomy or breast-conserving surgery were published, to the time of the Conference, breast-conserving surgery was performed on 44.8% of women with stage I and 25.8% with stage II breast cancer. These percentages increased to 54.9% and 35.2%, respectively, during the post-Conference period. While women with stage II breast cancer were less likely than women with stage I breast cancer to undergo breast-conserving surgery before and after the Conference, trends for age and education were attenuated after the Conference. Differences in the use of breast-conserving surgery observed before the Conference between countries of residence and among hospital types were also reduced after the Conference.
CONCLUSIONS: These findings suggest that the Conference recommendations had an effect on the adoption of breast-conserving surgery, particularly among groups who were previously least likely to undergo such surgery. Despite progress toward the Conference recommendation that the majority of women with early invasive breast cancer undergo breast-conserving surgery, the majority of women with stage II breast cancer undergo mastectomy.

Entities:  

Mesh:

Year:  1997        PMID: 9108764     DOI: 10.1001/archsurg.1997.01430280092014

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  7 in total

1.  Increasing trends in the use of breast-conserving surgery in California.

Authors:  C R Morris; R Cohen; R Schlag; W E Wright
Journal:  Am J Public Health       Date:  2000-02       Impact factor: 9.308

2.  Racial disparities and trends in radiation therapy after breast-conserving surgery for early-stage breast cancer in women, 1992 to 2002.

Authors:  L Du Xianglin; Beverly J Gor
Journal:  Ethn Dis       Date:  2007       Impact factor: 1.847

3.  Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews.

Authors:  Xianglin L Du; Charles R Key; Lois Dickie; Ronald Darling; George L Delclos; Kim Waller; Dong Zhang
Journal:  J Clin Epidemiol       Date:  2005-09-30       Impact factor: 6.437

4.  The "El Alamo" project (1990-1997): two consecutive hospital-based studies of breast cancer outcomes in Spain.

Authors:  M Martín; E Mahillo; A Llombart-Cussac; A Lluch; B Munarriz; M Pastor; E Alba; A Ruiz; A Antón; B Bermejo
Journal:  Clin Transl Oncol       Date:  2006-07       Impact factor: 3.405

Review 5.  Strategies for reducing regional variation in the use of surgery: a systematic review.

Authors:  Bradley N Reames; Sarah P Shubeck; John D Birkmeyer
Journal:  Ann Surg       Date:  2014-04       Impact factor: 12.969

6.  Breast conservation, mastectomy and axillary surgery in New South Wales women in 1992 and 1995.

Authors:  A Kricker; J Haskill; B K Armstrong
Journal:  Br J Cancer       Date:  2001-09-01       Impact factor: 7.640

7.  Magnetic resonance imaging and clinicopathological factors for the detection of occult nipple involvement in breast cancer patients.

Authors:  Wooseok Byon; Eunyoung Kim; Junseong Kwon; Yong Lai Park; Chanheun Park
Journal:  J Breast Cancer       Date:  2014-12-26       Impact factor: 3.588

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.